-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;text-align:justify;white-space:normal;line-height:27.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
us" style='margin:10px 0px 0px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
2px;">Guocai has already included 15 products, these two injections544px;line-height:24px;">544px;line-height:27.
2px;"> have been included in the 544px;line-height:24px;">544px;line-height:27.
2px;">fifth batch of injections.
Guocai544px;line-height:24px;">544px;line-height:27.
2px;"> has included 15 products in the fifth batch of injections, and the two injections544px;line-height:27.
2px;"> have been included in the fifth batch.
us" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
qq.
com/s/75e_aMvxWDIxE2N_4JplSg" data-miniprogram-type="text" data-miniprogram-servicetype="" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">According to data from Meinenet, in 2020, in public hospitals in key provinces and cities, the overall market size of musculoskeletal system drugs ranks eighth among 14 categories.
However, this category is favored by national centralized procurement.
weixin.
Anti-inflammatory drugs and antirheumatic drugs, the largest sub-category market share, fell 1.
81%.
Muscle relaxants, joint and muscle pain topical drugs The market share increased by 0.
59% and 0.
93%.
Guoshui won the bid to exchange price and volume, and the 2020 epidemic will affect the frequency of patients' visits to the hospital.
0 Chinese Drug Evaluation DatabaseSource: Meinenet MED2.
0 Chinese Drug Evaluation Database
So far, there are 13 products of musculoskeletal system drugs that have been reviewed but not included in the national procurement, including zoledronic acid injection, benzene Atracurium sulfatracurium injection has formed a pattern of "original research + 2 imitation".
At the end of public hospitals in key provinces and cities in 2020, zoledronic acid is the TOP1 species in the treatment of skeletal diseases, and cisatracurium is the TOP1 species in muscle relaxants.
Both varieties have high clinical value.
According to recent industry rumors, the fifth batch of national procurement is likely to be completed before July 1 this year.
us" style='margin:10px 0px 0px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
2px;">Class 1 new drug "takes off" Hengrui's first breakthrough to the top, multinational pharmaceutical companies are pressing harderus" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
2px;">Class 1 new drug "leads to fly" Hengrui makes its first breakthrough to the top, multinational pharmaceutical companies are stepping up to the top of the544px;line-height:24px;">544px;line-height:27.
2px;"> category 1 new drug "Lead to fly" Hengrui breaks through for the first time, and multinational pharmaceutical companies are stepping up to544px;line-height:27.
2px;"> "lead to fly" of class 1 new drugs Switzerland breaks through and climbs to the top for the first time, multinational pharmaceutical companies are pressing harderus" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
From 2015 to 2019, Beijing Tide Pharmaceuticals ranked TOP1 with a market share of more than 10%.
In 2020, Hengrui successfully broke through and took the top spot.
The leading position of the musculoskeletal system drug market has always been held by domestic pharmaceutical companies.
From 2015 to 2019, Beijing Tide Pharmaceuticals ranked TOP1 with a market share of more than 10%.
In 2020, Hengrui successfully broke through and took the top spot.
The new drug is a COX-2 selective inhibitor anti-inflammatory and analgesic drug for specific targets developed independently by the company for 14 years.
It was approved for listing in June 2011.
After entering the National Medical Insurance Catalog in 2017, sales began to increase rapidly.
In 2018, the terminal sales of public hospitals in key provinces and cities exceeded the 100 million mark, and the growth rate from 2019 to 2020 reached 58.
53% and 19.
49%.
.
Hengrui’s "God Assistant" is the company’s first innovative drug, Irecoxib Tablets.
The new drug is a COX-2 selective inhibitor anti-inflammatory and analgesic drug for specific targets developed independently by the company for 14 years.
It was approved for listing in June 2011.
After entering the National Medical Insurance Catalog in 2017, sales began to increase rapidly.
In 2018, the terminal sales of public hospitals in key provinces and cities exceeded the 100 million mark, and the growth rate from 2019 to 2020 reached 58.
53% and 19.
49%.
.
The biological drug SHR-1222 injection has entered phase I clinical trials, and SHR0302 tablets and SHR4640 tablets have entered phase III clinical trials, with rapid progress.
Pfizer's market share has risen from 3.
61% in 2015 to 4.
95% in 2020, and Merck has increased from 2.
91% in 2015 to 3.
85% in 2020.
Multinational pharmaceutical companies successfully rejected other domestic pharmaceutical companies and became the strongest rivals of Hengrui and Beijing Tide Pharmaceuticals.
Whether Novartis will fight for low prices and maintain its position is worthy of attention; in addition, Merck’s Shugeng Sodium Gluconate Injection has a sales growth rate of up to 2019-2020 758.
10% and 140.
36% are expected to grow into products with sales of over 100 million yuan in 2021, becoming a new boost to the company's performance.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
2px;">The ranking of TOP10 products was reshuffled.
This domestic plaster successfully forced the retreat of the original research544px;line-height:24px;">544px;line-height:27.
2px;"> TOP10 product ranking.
This domestic plaster successfully forced the retreat of the original research544px;line-height:27.
2px;"> TOP10 product ranking.
This domestic plaster successfully forced the retreat of the original research.
us" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
Among them, flurbiprofen gel plaster is the only plaster product on the list, and recombinant human for injection Ⅱ Tumor necrosis factor receptor-antibody fusion protein is the only biologic drug on the list, and ketorolac tromethamine injection is a newcomer.
The tenth place in 2019, glucosamine sulfate capsules fell to 2020 Seventeenth place.
Beijing Tide Pharmaceuticals promoted domestically through the sale of imported subpackaged products in 2010, and began to sell products independently developed and produced by the company in 2011.
The domestically produced flurbiprofen gel patch retains the Japanese polymer hydrogel patch technology, and has been widely recognized after it went on the market.
At present, the original research product is no longer visible in the terminal of public hospitals in key provinces and cities, and it is only in retail There is a small amount of sales in the market, which can be said to be a perfect example of domestically replacing original research.
At the same time, flurbiprofen, as the leading product of Beijing Tide Pharmaceuticals, has reduced the sales scale of injections under the impact of national procurement, and the rapid increase in plaster sales is expected to help the company continue to maintain its leading position.
The first domestic company to be approved for listing in 2005 was Sansheng Guojian Pharmaceutical, and Pfizer’s etanercept was launched in 2010.
It was only approved to be imported into China in 2016.
Taking advantage of the opportunity of domestically produced new drugs to be marketed before imported drugs, Sansheng Guojian Pharmaceutical has gained a good market space.
Shanghai Saijin Biological and Hisun Pharmaceutical were approved for listing in 2011 and 2015 respectively.
The market for this product is currently controlled by domestic pharmaceutical companies.
In recent years, the sales of this product in public hospitals in key provinces and cities have risen rapidly.
In 2018, it exceeded 100 million yuan and reached 200 million yuan in 2019.
In 2020, the growth rate will remain around 14% under the influence of the epidemic.
Among the 6 companies with approvals, Shandong New Era Pharmaceuticals leads the market, and Chengdu Better Pharmaceuticals was approved and reviewed in 2019, with a growth rate of 128900.
00% in 2020, rushing to the second place in one fell swoop.
At present, only one company has reviewed the product, and the supplementary applications for consistency evaluation of the three companies are under review.
The sales of Chengdu Better Pharmaceuticals is expected to continue to rise in the short term.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
2px;">Imported new drugs and domestic first imitations have entered the market one after another, Qilu new products have a major outbreak of544px;line-height:24px;">544px;line-height:27.
2px;"> imported new drugs, domestic first imitations have entered the market one after another, Qilu new products have a large outbreak of544px;line-height:27.
2px;"> imported new drugs, domestic first imitations have entered the market one after another, Qilu new products have a big outbreakus" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
0 Chinese Drug Evaluation Database
The product is an active vitamin D3 derivative for the treatment of osteoporosis, which was first launched in Japan in 2011.
In vitro experiments have proved that the product acts on human osteoclast precursor cells and inhibits the formation of osteoclasts; another animal experiment has proved that the product can promote the absorption of calcium in the small intestine and increase the blood calcium concentration; the product can also improve bone metabolism And promote calcium absorption, improve bone density and bone strength, thereby reducing the incidence of osteoporotic fractures.
The drug is used for the treatment of X-linked hypophosphatemia (XLH) in adult and 1-year-old children.
The product was listed in the "second batch of clinically urgently needed overseas "List of new drugs", the new indication was approved in March this year, which can be used for tumor-related osteomalacia.
Minodronic acid is a new type of nitrogen-containing aromatic heterocyclic bisphosphonic acid compound, which can be used as a first-line drug for the treatment of osteoporosis.
The original drug was jointly developed by Japan Ono Pharmaceutical Co.
, Ltd.
and Japan Astellas Pharmaceutical Co.
, Ltd.
, in 2009 It was approved to be listed in Japan for the first time in January of 2009 and has not been listed in the domestic market so far.
Tasly has been approved according to the 3 types of imitations and deemed to have been reviewed.
The approved indication is the treatment of osteoporosis in postmenopausal women.
In February 2019, it applied for 3 types of generic listings.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug” and won the domestic first place in October 2020.
Imitation, the indication is for the prevention and treatment of malignant high fever.
0 Chinese Drug Evaluation Database
Micuronium chloride is a benzyl isoquinoline compound.
It is a highly selective, short-acting, non-depolarizing neuromuscular blocker.
It has the characteristics of quick recovery after action and can be used as an auxiliary drug for general anesthesia.
Relax the skeletal muscles to facilitate tracheal intubation and mechanical ventilation.
At present, only GlaxoSmithKline’s Micuronium Chloride injection is on sale in China, which is a national medical insurance category B product.
Sales in recent years have not been outstanding.
Risdiplam is an RNA splicing regulator developed by Roche for the treatment of spinal muscular atrophy (SMA).
The drug has been granted Orphan Drug Designation and Fast Track Designation by the US FDA and is expected to be approved in the US this year.
Roche said that in addition to China, the company has also submitted applications in Brazil, Chile, Indonesia, Russia, South Korea and other places, and plans to submit listing applications to European EMA and other countries and regions.
According to the comprehensive database of the MID Drug Index of Meinenet, Qilu’s approved products in the biopharmaceutical field include recombinant human interleukin-11 for injection, pegylated recombinant human granulocyte stimulating factor injection, bevacizumab injection and If the recombinant human granulocyte stimulating factor injection, the company's recombinant human tumor necrosis factor receptor-antibody fusion protein for injection is successfully approved, it can enhance the company's market position in the field of biopharmaceuticals.
0 Chinese Drug Evaluation Database
Pfizer declared for import in May 2020, while Qilu Pharmaceutical declared for imitation listing in August of the same year.
At present, CSPC Ouyi Pharmaceutical’s 3 types of imitations have also been accepted.
Will the original research be approved for import in the end or will Qilu win the first imitation to seize the opportunity? We will continue to monitor the latest situation.
Sichuan Creed Pharma’s application for the 4 types of generic listing of Micuronium Chloride Injection has entered the "under review" status.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
Sichuan Creed Pharma’s application for the 4 types of generic listing of Micuronium Chloride Injection has entered the "under review" status.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
Sichuan Creed Pharma’s application for the 4 types of generic listing of Micuronium Chloride Injection has entered the "under review" status.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
Sichuan Creed Pharma’s application for the 4 types of generic listing of Micuronium Chloride Injection has entered the "under review" status.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
Sichuan Creed Pharma’s application for the 4 types of generic listing of Micuronium Chloride Injection has entered the "under review" status.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
New members of the pharmaceutical and biological medicine) market.
In 2020, the terminal musculoskeletal system drug market in public hospitals in key provinces and cities exceeded 7 billion yuan.
The TOP1 company was captured by Hengrui for the first time.
With the overall sales decline, this domestic plaster has risen against the trend.
The fifth batch of national procurement is like an arrow, and three of these two injections have been collected.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
us" style='margin:10px 0px 0px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;line-height:24px;">544px;line-height:27.
2px;">Guocai has included 15 products, and these two injections sprint for the fifth batch
544px;line-height:24px;">544px;line-height:27.
2px;">Guocai has included 15 products, and these two injections sprint for the fifth batch
544px;line-height:24px;">544px;line-height:27.
2px;">Guocai has included 15 products, and these two injections sprint for the fifth batch
544px;line-height:24px;">544px;line-height:27.
2px;">Guocai has included 15 products, and these two injections sprint for the fifth batch
2px;">Guocai has already included 15 products, these two injections544px;line-height:24px;">544px;line-height:27.
2px;"> have been included in the 544px;line-height:24px;">544px;line-height:27.
2px;">fifth batch of injections.
Guocai544px;line-height:24px;">544px;line-height:27.
2px;"> has included 15 products in the fifth batch of injections, and the two injections544px;line-height:27.
2px;"> have been included in the fifth batch.
us" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> weixin.
qq.
com/s/75e_aMvxWDIxE2N_4JplSg" data-miniprogram-type="text" data-miniprogram-servicetype="" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">According to data from Meinenet, in 2020, in public hospitals in key provinces and cities, the overall market size of musculoskeletal system drugs ranks eighth among 14 categories.
However, this category is favored by national centralized procurement.
weixin.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 1: The status of musculoskeletal system drugs that have been included in the national collection
Table 1: The status of musculoskeletal system drugs that have been included in the national collection544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Shanghai Sunshine Pharmaceutical Purchasing Network, * is the lowest bid-winning company
Source: Shanghai Sunshine Pharmaceutical Purchasing Network, * is the lowest bid-winning company544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Guoshui won the bid to exchange price and volume, and the 2020 epidemic will affect the frequency of patients' visits to the hospital.
Anti-inflammatory drugs and antirheumatic drugs, the largest sub-category market share, fell 1.
81%.
Muscle relaxants, joint and muscle pain topical drugs The market share increased by 0.
59% and 0.
93%.
Guoshui won the bid to exchange price and volume, and the 2020 epidemic will affect the frequency of patients' visits to the hospital.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 2: Situation of products that have been reviewed (including deemed review) but have not yet been included in centralized procurement
Table 2: Situation of products that have been reviewed (including deemed review) but have not yet been included in centralized procurement544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Meinenet MED2.
0 Chinese Drug Evaluation DatabaseSource: Meinenet MED2.
0 Chinese Drug Evaluation Database
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> According to recent industry rumors, the fifth batch of national procurement is likely to be completed before July 1 this year.
So far, there are 13 products of musculoskeletal system drugs that have been reviewed but not included in the national procurement, including zoledronic acid injection, benzene Atracurium sulfatracurium injection has formed a pattern of "original research + 2 imitation".
At the end of public hospitals in key provinces and cities in 2020, zoledronic acid is the TOP1 species in the treatment of skeletal diseases, and cisatracurium is the TOP1 species in muscle relaxants.
Both varieties have high clinical value.
According to recent industry rumors, the fifth batch of national procurement is likely to be completed before July 1 this year.
us" style='margin:10px 0px 0px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;line-height:24px;">544px;line-height:27.
2px;">Class 1 new drug "takes off" Hengrui's first breakthrough to the top, multinational pharmaceutical companies are pressing harderus" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;line-height:24px;">544px;line-height:27.
2px;">Class 1 new drug "takes off" Hengrui's first breakthrough to the top, multinational pharmaceutical companies are pressing harder
544px;line-height:24px;">544px;line-height:27.
2px;">Class 1 new drug "takes off" Hengrui's first breakthrough to the top, multinational pharmaceutical companies are pressing harder
544px;line-height:24px;">544px;line-height:27.
2px;">Class 1 new drug "takes off" Hengrui's first breakthrough to the top, multinational pharmaceutical companies are pressing harder
2px;">Class 1 new drug "leads to fly" Hengrui makes its first breakthrough to the top, multinational pharmaceutical companies are stepping up to the top of the544px;line-height:24px;">544px;line-height:27.
2px;"> category 1 new drug "Lead to fly" Hengrui breaks through for the first time, and multinational pharmaceutical companies are stepping up to544px;line-height:27.
2px;"> "lead to fly" of class 1 new drugs Switzerland breaks through and climbs to the top for the first time, multinational pharmaceutical companies are pressing harderus" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 3: Market share of TOP5 companies in the musculoskeletal system
Table 3: Market share of TOP5 companies in the musculoskeletal system544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> The leading position of the musculoskeletal system drug market has always been held by domestic pharmaceutical companies.
From 2015 to 2019, Beijing Tide Pharmaceuticals ranked TOP1 with a market share of more than 10%.
In 2020, Hengrui successfully broke through and took the top spot.
The leading position of the musculoskeletal system drug market has always been held by domestic pharmaceutical companies.
From 2015 to 2019, Beijing Tide Pharmaceuticals ranked TOP1 with a market share of more than 10%.
In 2020, Hengrui successfully broke through and took the top spot.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Hengrui’s "God Assistant" is the company’s first innovative drug, Irecoxib Tablets.
The new drug is a COX-2 selective inhibitor anti-inflammatory and analgesic drug for specific targets developed independently by the company for 14 years.
It was approved for listing in June 2011.
After entering the National Medical Insurance Catalog in 2017, sales began to increase rapidly.
In 2018, the terminal sales of public hospitals in key provinces and cities exceeded the 100 million mark, and the growth rate from 2019 to 2020 reached 58.
53% and 19.
49%.
.
Hengrui’s "God Assistant" is the company’s first innovative drug, Irecoxib Tablets.
The new drug is a COX-2 selective inhibitor anti-inflammatory and analgesic drug for specific targets developed independently by the company for 14 years.
It was approved for listing in June 2011.
After entering the National Medical Insurance Catalog in 2017, sales began to increase rapidly.
In 2018, the terminal sales of public hospitals in key provinces and cities exceeded the 100 million mark, and the growth rate from 2019 to 2020 reached 58.
53% and 19.
49%.
.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 4: Research status of Hengrui musculoskeletal system class 1 new drugs
Table 4: Research status of Hengrui musculoskeletal system class 1 new drugs544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: China Drug Clinical Trial Publicity Library of Meinenet
Source: China Drug Clinical Trial Publicity Library of Meinenet544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Currently, Hengrui has three Class 1 new drugs under development in the field of musculoskeletal system drugs.
The biological drug SHR-1222 injection has entered phase I clinical trials, and SHR0302 tablets and SHR4640 tablets have entered phase III clinical trials, with rapid progress.
The biological drug SHR-1222 injection has entered phase I clinical trials, and SHR0302 tablets and SHR4640 tablets have entered phase III clinical trials, with rapid progress.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Although the three multinational pharmaceutical companies Pfizer, Novartis and Merck have less than 5% market share in 2020, their strength cannot be underestimated.
Pfizer's market share has risen from 3.
61% in 2015 to 4.
95% in 2020, and Merck has increased from 2.
91% in 2015 to 3.
85% in 2020.
Multinational pharmaceutical companies successfully rejected other domestic pharmaceutical companies and became the strongest rivals of Hengrui and Beijing Tide Pharmaceuticals.
Pfizer's market share has risen from 3.
61% in 2015 to 4.
95% in 2020, and Merck has increased from 2.
91% in 2015 to 3.
85% in 2020.
Multinational pharmaceutical companies successfully rejected other domestic pharmaceutical companies and became the strongest rivals of Hengrui and Beijing Tide Pharmaceuticals.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> From the perspective of leading products, Pfizer’s parecoxib sodium for injection and Merck’s etoricoxib tablets have been included in the national procurement, and the winning bidders are domestic pharmaceutical companies, and the share of the original research pharmaceutical companies is expected to be compressed; and Novartis’s Zoledronic acid injection is expected to be included in the fifth batch of catalogues.
Whether Novartis will fight for low prices and maintain its position is worthy of attention; in addition, Merck’s Shugeng Sodium Gluconate Injection has a sales growth rate of up to 2019-2020 758.
10% and 140.
36% are expected to grow into products with sales of over 100 million yuan in 2021, becoming a new boost to the company's performance.
Whether Novartis will fight for low prices and maintain its position is worthy of attention; in addition, Merck’s Shugeng Sodium Gluconate Injection has a sales growth rate of up to 2019-2020 758.
10% and 140.
36% are expected to grow into products with sales of over 100 million yuan in 2021, becoming a new boost to the company's performance.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;line-height:24px;">544px;line-height:27.
2px;">The ranking of TOP10 products has been reshuffled.
This domestic plaster successfully forced the original research to be retreated
544px;line-height:24px;">544px;line-height:27.
2px;">The ranking of TOP10 products has been reshuffled.
This domestic plaster successfully forced the original research to be retreated
544px;line-height:24px;">544px;line-height:27.
2px;">The ranking of TOP10 products has been reshuffled.
This domestic plaster successfully forced the original research to be retreated
544px;line-height:24px;">544px;line-height:27.
2px;">The ranking of TOP10 products has been reshuffled.
This domestic plaster successfully forced the original research to be retreated
2px;">The ranking of TOP10 products was reshuffled.
This domestic plaster successfully forced the retreat of the original research544px;line-height:24px;">544px;line-height:27.
2px;"> TOP10 product ranking.
This domestic plaster successfully forced the retreat of the original research544px;line-height:27.
2px;"> TOP10 product ranking.
This domestic plaster successfully forced the retreat of the original research.
us" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 5: 2020 TOP10 musculoskeletal system drug products
Table 5: 2020 TOP10 musculoskeletal system drug products544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Terminal competition pattern of public hospitals in key provinces and cities
Source: Terminal competition pattern of public hospitals in key provinces and cities544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> In 2020, the total market share of TOP10 products for terminal musculoskeletal system drugs in public hospitals in key provinces and cities accounted for half of the total market share, and the ranking of 6 products rose.
Among them, flurbiprofen gel plaster is the only plaster product on the list, and recombinant human for injection Ⅱ Tumor necrosis factor receptor-antibody fusion protein is the only biologic drug on the list, and ketorolac tromethamine injection is a newcomer.
The tenth place in 2019, glucosamine sulfate capsules fell to 2020 Seventeenth place.
Among them, flurbiprofen gel plaster is the only plaster product on the list, and recombinant human for injection Ⅱ Tumor necrosis factor receptor-antibody fusion protein is the only biologic drug on the list, and ketorolac tromethamine injection is a newcomer.
The tenth place in 2019, glucosamine sulfate capsules fell to 2020 Seventeenth place.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Figure 1: Sales of flurbiprofen gel plaster
Figure 1: Sales of flurbiprofen gel plaster544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Terminal competition pattern of public hospitals in key provinces and cities
Source: Terminal competition pattern of public hospitals in key provinces and cities544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Flurbiprofen gel plaster is the original research product of Japan's Mikasa Pharmaceuticals.
Beijing Tide Pharmaceuticals promoted domestically through the sale of imported subpackaged products in 2010, and began to sell products independently developed and produced by the company in 2011.
The domestically produced flurbiprofen gel patch retains the Japanese polymer hydrogel patch technology, and has been widely recognized after it went on the market.
At present, the original research product is no longer visible in the terminal of public hospitals in key provinces and cities, and it is only in retail There is a small amount of sales in the market, which can be said to be a perfect example of domestically replacing original research.
At the same time, flurbiprofen, as the leading product of Beijing Tide Pharmaceuticals, has reduced the sales scale of injections under the impact of national procurement, and the rapid increase in plaster sales is expected to help the company continue to maintain its leading position.
Beijing Tide Pharmaceuticals promoted domestically through the sale of imported subpackaged products in 2010, and began to sell products independently developed and produced by the company in 2011.
The domestically produced flurbiprofen gel patch retains the Japanese polymer hydrogel patch technology, and has been widely recognized after it went on the market.
At present, the original research product is no longer visible in the terminal of public hospitals in key provinces and cities, and it is only in retail There is a small amount of sales in the market, which can be said to be a perfect example of domestically replacing original research.
At the same time, flurbiprofen, as the leading product of Beijing Tide Pharmaceuticals, has reduced the sales scale of injections under the impact of national procurement, and the rapid increase in plaster sales is expected to help the company continue to maintain its leading position.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Figure 2: Enterprise competition landscape of recombinant human tumor necrosis factor receptor-antibody fusion protein for injection in 2020
Figure 2: Enterprise competition landscape of recombinant human tumor necrosis factor receptor-antibody fusion protein for injection in 2020544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Terminal competition pattern of public hospitals in key provinces and cities
Source: Terminal competition pattern of public hospitals in key provinces and cities544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Recombinant human tumor necrosis factor receptor-antibody fusion protein for injection is the only biologic drug on the list.
The first domestic company to be approved for listing in 2005 was Sansheng Guojian Pharmaceutical, and Pfizer’s etanercept was launched in 2010.
It was only approved to be imported into China in 2016.
Taking advantage of the opportunity of domestically produced new drugs to be marketed before imported drugs, Sansheng Guojian Pharmaceutical has gained a good market space.
Shanghai Saijin Biological and Hisun Pharmaceutical were approved for listing in 2011 and 2015 respectively.
The market for this product is currently controlled by domestic pharmaceutical companies.
The first domestic company to be approved for listing in 2005 was Sansheng Guojian Pharmaceutical, and Pfizer’s etanercept was launched in 2010.
It was only approved to be imported into China in 2016.
Taking advantage of the opportunity of domestically produced new drugs to be marketed before imported drugs, Sansheng Guojian Pharmaceutical has gained a good market space.
Shanghai Saijin Biological and Hisun Pharmaceutical were approved for listing in 2011 and 2015 respectively.
The market for this product is currently controlled by domestic pharmaceutical companies.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Ketorolac tromethamine injection is a drug in the National Medical Insurance Catalogue and a postoperative analgesic recommended by the Anesthesiology Branch of the Chinese Medical Association.
In recent years, the sales of this product in public hospitals in key provinces and cities have risen rapidly.
In 2018, it exceeded 100 million yuan and reached 200 million yuan in 2019.
In 2020, the growth rate will remain around 14% under the influence of the epidemic.
Among the 6 companies with approvals, Shandong New Era Pharmaceuticals leads the market, and Chengdu Better Pharmaceuticals was approved and reviewed in 2019, with a growth rate of 128900.
00% in 2020, rushing to the second place in one fell swoop.
At present, only one company has reviewed the product, and the supplementary applications for consistency evaluation of the three companies are under review.
The sales of Chengdu Better Pharmaceuticals is expected to continue to rise in the short term.
In recent years, the sales of this product in public hospitals in key provinces and cities have risen rapidly.
In 2018, it exceeded 100 million yuan and reached 200 million yuan in 2019.
In 2020, the growth rate will remain around 14% under the influence of the epidemic.
Among the 6 companies with approvals, Shandong New Era Pharmaceuticals leads the market, and Chengdu Better Pharmaceuticals was approved and reviewed in 2019, with a growth rate of 128900.
00% in 2020, rushing to the second place in one fell swoop.
At present, only one company has reviewed the product, and the supplementary applications for consistency evaluation of the three companies are under review.
The sales of Chengdu Better Pharmaceuticals is expected to continue to rise in the short term.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;line-height:24px;">544px;line-height:27.
2px;">Imported new drugs and domestic first imitations have entered the market one after another, and Qilu new products have exploded
544px;line-height:24px;">544px;line-height:27.
2px;">Imported new drugs and domestic first imitations have entered the market one after another, and Qilu new products have exploded
544px;line-height:24px;">544px;line-height:27.
2px;">Imported new drugs and domestic first imitations have entered the market one after another, and Qilu new products have exploded
544px;line-height:24px;">544px;line-height:27.
2px;">Imported new drugs and domestic first imitations have entered the market one after another, and Qilu new products have exploded
2px;">Imported new drugs and domestic first imitations have entered the market one after another, Qilu new products have a major outbreak of544px;line-height:24px;">544px;line-height:27.
2px;"> imported new drugs, domestic first imitations have entered the market one after another, Qilu new products have a large outbreak of544px;line-height:27.
2px;"> imported new drugs, domestic first imitations have entered the market one after another, Qilu new products have a big outbreakus" style='margin:0px 0px 8px;padding:0px;max-width:100%;color:#333333;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;line-height:25.
6px;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 6: Status of musculoskeletal system drugs approved for import/marketing from 2020 to now
Table 6: Status of musculoskeletal system drugs approved for import/marketing from 2020 to now544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> In 2020, Roche’s Sino-foreign pharmaceuticals new drug idecalcitol soft capsule was approved for marketing in China.
The product is an active vitamin D3 derivative for the treatment of osteoporosis, which was first launched in Japan in 2011.
In vitro experiments have proved that the product acts on human osteoclast precursor cells and inhibits the formation of osteoclasts; another animal experiment has proved that the product can promote the absorption of calcium in the small intestine and increase the blood calcium concentration; the product can also improve bone metabolism And promote calcium absorption, improve bone density and bone strength, thereby reducing the incidence of osteoporotic fractures.
The product is an active vitamin D3 derivative for the treatment of osteoporosis, which was first launched in Japan in 2011.
In vitro experiments have proved that the product acts on human osteoclast precursor cells and inhibits the formation of osteoclasts; another animal experiment has proved that the product can promote the absorption of calcium in the small intestine and increase the blood calcium concentration; the product can also improve bone metabolism And promote calcium absorption, improve bone density and bone strength, thereby reducing the incidence of osteoporotic fractures.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> In 2021, brozoyuumab injection was approved to be imported into the country.
The drug is used for the treatment of X-linked hypophosphatemia (XLH) in adult and 1-year-old children.
The product was listed in the "second batch of clinically urgently needed overseas "List of new drugs", the new indication was approved in March this year, which can be used for tumor-related osteomalacia.
The drug is used for the treatment of X-linked hypophosphatemia (XLH) in adult and 1-year-old children.
The product was listed in the "second batch of clinically urgently needed overseas "List of new drugs", the new indication was approved in March this year, which can be used for tumor-related osteomalacia.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> In terms of generic drugs, Jiangsu Tasly Diyi Pharmaceutical and Livzon Group Livzon Pharmaceutical Factory both won a domestic first imitation in 2020.
Minodronic acid is a new type of nitrogen-containing aromatic heterocyclic bisphosphonic acid compound, which can be used as a first-line drug for the treatment of osteoporosis.
The original drug was jointly developed by Japan Ono Pharmaceutical Co.
, Ltd.
and Japan Astellas Pharmaceutical Co.
, Ltd.
, in 2009 It was approved to be listed in Japan for the first time in January of 2009 and has not been listed in the domestic market so far.
Tasly has been approved according to the 3 types of imitations and deemed to have been reviewed.
The approved indication is the treatment of osteoporosis in postmenopausal women.
Minodronic acid is a new type of nitrogen-containing aromatic heterocyclic bisphosphonic acid compound, which can be used as a first-line drug for the treatment of osteoporosis.
The original drug was jointly developed by Japan Ono Pharmaceutical Co.
, Ltd.
and Japan Astellas Pharmaceutical Co.
, Ltd.
, in 2009 It was approved to be listed in Japan for the first time in January of 2009 and has not been listed in the domestic market so far.
Tasly has been approved according to the 3 types of imitations and deemed to have been reviewed.
The approved indication is the treatment of osteoporosis in postmenopausal women.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Livzon’s dantrolene sodium for injection has undergone 10 years of research and development.
In February 2019, it applied for 3 types of generic listings.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug” and won the domestic first place in October 2020.
Imitation, the indication is for the prevention and treatment of malignant high fever.
In February 2019, it applied for 3 types of generic listings.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug” and won the domestic first place in October 2020.
Imitation, the indication is for the prevention and treatment of malignant high fever.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Table 7: Imported new drugs under review since 2018/Musculoskeletal system drugs that have impacted the first domestic imitation
Table 7: Imported new drugs under review since 2018/Musculoskeletal system drugs that have impacted the first domestic imitation544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Recently, Sichuan Creed Pharma's application for the imitation of Micuronium Chloride Injection for 4 types of imitations has entered the "under review" status, and it is expected to win the first imitation + first review in China.
Micuronium chloride is a benzyl isoquinoline compound.
It is a highly selective, short-acting, non-depolarizing neuromuscular blocker.
It has the characteristics of quick recovery after action and can be used as an auxiliary drug for general anesthesia.
Relax the skeletal muscles to facilitate tracheal intubation and mechanical ventilation.
At present, only GlaxoSmithKline’s Micuronium Chloride injection is on sale in China, which is a national medical insurance category B product.
Sales in recent years have not been outstanding.
Micuronium chloride is a benzyl isoquinoline compound.
It is a highly selective, short-acting, non-depolarizing neuromuscular blocker.
It has the characteristics of quick recovery after action and can be used as an auxiliary drug for general anesthesia.
Relax the skeletal muscles to facilitate tracheal intubation and mechanical ventilation.
At present, only GlaxoSmithKline’s Micuronium Chloride injection is on sale in China, which is a national medical insurance category B product.
Sales in recent years have not been outstanding.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> In terms of imported new drugs under review, Roche's Risdiplam powder for oral liquid has attracted much attention from the market.
Risdiplam is an RNA splicing regulator developed by Roche for the treatment of spinal muscular atrophy (SMA).
The drug has been granted Orphan Drug Designation and Fast Track Designation by the US FDA and is expected to be approved in the US this year.
Roche said that in addition to China, the company has also submitted applications in Brazil, Chile, Indonesia, Russia, South Korea and other places, and plans to submit listing applications to European EMA and other countries and regions.
Risdiplam is an RNA splicing regulator developed by Roche for the treatment of spinal muscular atrophy (SMA).
The drug has been granted Orphan Drug Designation and Fast Track Designation by the US FDA and is expected to be approved in the US this year.
Roche said that in addition to China, the company has also submitted applications in Brazil, Chile, Indonesia, Russia, South Korea and other places, and plans to submit listing applications to European EMA and other countries and regions.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> In terms of domestic new drugs, Qilu Pharmaceutical is expected to become the fourth approved company for recombinant human tumor necrosis factor receptor-antibody fusion protein for injection.
According to the comprehensive database of the MID Drug Index of Meinenet, Qilu’s approved products in the biopharmaceutical field include recombinant human interleukin-11 for injection, pegylated recombinant human granulocyte stimulating factor injection, bevacizumab injection and If the recombinant human granulocyte stimulating factor injection, the company's recombinant human tumor necrosis factor receptor-antibody fusion protein for injection is successfully approved, it can enhance the company's market position in the field of biopharmaceuticals.
According to the comprehensive database of the MID Drug Index of Meinenet, Qilu’s approved products in the biopharmaceutical field include recombinant human interleukin-11 for injection, pegylated recombinant human granulocyte stimulating factor injection, bevacizumab injection and If the recombinant human granulocyte stimulating factor injection, the company's recombinant human tumor necrosis factor receptor-antibody fusion protein for injection is successfully approved, it can enhance the company's market position in the field of biopharmaceuticals.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Figure 3: Import/Imitation Listing Application Status of Tofacitib Citrate Sustained-Release Tablets
Figure 3: Import/Imitation Listing Application Status of Tofacitib Citrate Sustained-Release Tablets544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> At present, there is no tofacitib citrate sustained-release tablets in China.
Pfizer declared for import in May 2020, while Qilu Pharmaceutical declared for imitation listing in August of the same year.
At present, CSPC Ouyi Pharmaceutical’s 3 types of imitations have also been accepted.
Will the original research be approved for import in the end or will Qilu win the first imitation to seize the opportunity? We will continue to monitor the latest situation.
Pfizer declared for import in May 2020, while Qilu Pharmaceutical declared for imitation listing in August of the same year.
At present, CSPC Ouyi Pharmaceutical’s 3 types of imitations have also been accepted.
Will the original research be approved for import in the end or will Qilu win the first imitation to seize the opportunity? We will continue to monitor the latest situation.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> ，，，2018。，、，，，、、、、、、、15，。
，，，2018。，、，，，、、、、、、、15，。
